These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1641 related articles for article (PubMed ID: 32887954)

  • 1. Immunological considerations for COVID-19 vaccine strategies.
    Jeyanathan M; Afkhami S; Smaill F; Miller MS; Lichty BD; Xing Z
    Nat Rev Immunol; 2020 Oct; 20(10):615-632. PubMed ID: 32887954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of SARS-CoV-2 vaccine candidates.
    Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
    Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.
    Samrat SK; Tharappel AM; Li Z; Li H
    Virus Res; 2020 Oct; 288():198141. PubMed ID: 32846196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.
    Coudeville L; Gomez GB; Jollivet O; Harris RC; Thommes E; Druelles S; Chit A; Chaves SS; Mahé C
    Vaccine; 2020 Nov; 38(48):7588-7595. PubMed ID: 33097312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Keeping track of the SARS-CoV-2 vaccine pipeline.
    Parker EPK; Shrotri M; Kampmann B
    Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronavirus vaccine-associated lung immunopathology-what is the significance?
    Bottazzi ME; Strych U; Hotez PJ; Corry DB
    Microbes Infect; 2020 Oct; 22(9):403-404. PubMed ID: 32599077
    [No Abstract]   [Full Text] [Related]  

  • 9. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
    Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
    Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
    Al-Kassmy J; Pedersen J; Kobinger G
    Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine and boosted immunity: Nothing ad interim to do?
    Roncati L; Vadalà M; Corazzari V; Palmieri B
    Vaccine; 2020 Nov; 38(48):7581-7584. PubMed ID: 33071005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.
    Khalaj-Hedayati A
    J Immunol Res; 2020; 2020():7201752. PubMed ID: 32695833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 herd immunity: where are we?
    Fontanet A; Cauchemez S
    Nat Rev Immunol; 2020 Oct; 20(10):583-584. PubMed ID: 32908300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-reactive memory T cells and herd immunity to SARS-CoV-2.
    Lipsitch M; Grad YH; Sette A; Crotty S
    Nat Rev Immunol; 2020 Nov; 20(11):709-713. PubMed ID: 33024281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine.
    Pregelj L; Hine DC; Oyola-Lozada MG; Munro TP
    Trends Biotechnol; 2020 Sep; 38(9):943-947. PubMed ID: 32600777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccine trials: Duty of care and standard of prevention considerations.
    Singh JA
    Vaccine; 2020 Nov; 38(48):7578-7580. PubMed ID: 33069443
    [No Abstract]   [Full Text] [Related]  

  • 19. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.
    Galili U
    Vaccine; 2020 Sep; 38(42):6487-6499. PubMed ID: 32907757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine therapy during the COVID-19 pandemic.
    Rudnicka L; Glowacka P; Goldust M; Sikora M; Sar-Pomian M; Rakowska A; Samochocki Z; Olszewska M
    J Am Acad Dermatol; 2020 Aug; 83(2):e151-e152. PubMed ID: 32376422
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 83.